Friday, July 03, 2015 6:17:02 PM
so Hyeryun Choe became a big PS Targeting backer back in March of 2014 and also received some money to investigate further. That is about $2.3 Million all to investigate PS = Phosphatidylserine, or shall we say flipped PS and flipped PS is "where the trouble begins"., according to Hyeryun's direct quote below.
-----------------------------------------------
-----------------------------------------------------
Now, wouldn't it be nice if others knew about this and it looks like Peter Kolchinsky certainly does and he certainly must have been asked about PS Targeting and all of this... is part of the reason why so many would like to conceal much of this information that is slowly reaching the masses.
----------------------------------------------------
Peter Kolchinsky as one of the Authors next to Hyerun Choe
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99185608&txt2find=choe|bavituximab
---------------------------------------------------
a nice Harvard party it seems to be and heck, even Cramer went to Harvard night school... and Dr. Jack West (who lost all credibility with me...) because he must have ties that do not want to spread the good word of PS Targeting and went to Harvard as well. One Harvard grad that will help Hyeryun Choe further the research of PS Targeting will be = Mike Farzan. Now listen and read carefully and connect some behind the scenes dots:
Hyeryun Choe just rec'd $2.3 Million to further PS Targeting research back in March 2014, which this author reminds you of below... yet no digging deeper and where the trouble begins = flipped PS as I show you above!...and now Mike Farzan is awaiting some additional funds and for PS Targeting as well? I bet 100% yes. When he applied for those funds, do you think it included research that was based on his wifes PS Targeting research from the past year ?? Think of it hard and long, read the above article twice and below twice... and you will conclude a big yes!
....because not all Harvard grads like Dr. West or Cramer will twist the truths for their monetary benefits.
---------------------------------------------------
------------------------------------------------------
Now, for the last time, don't you think its quite significant that the latest article where Mike Farzan is awaiting funding for HIV/Ebola..etc just may place PS Targeting on the map for good? Do you think it is foolish for some to keep reminding you of dilution or the old times... and some don't like to remind you of "where the trouble begins = flipped PS" ???
Read them both again, slowly.... and will Peregrine require 4 Billion shares to handle the demand in soon enough time? Hell yes.
Would you want to buy at $10..or $15..or higher.. vs $1.30 ? Well that is up to you after doing your own due diligence.
Now back to mowing some lawns and damn, Richard Lerner to Michael Marletta ... and Sanofi Sunrise Katherin Bowdish and team all coming together in 2014 as well. These puzzle pieces play a part as well.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:31:12 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM